1-Boc-3-氰基氮杂环丁烷 | 142253-54-1

• 物质功能分类: 化学试剂 - 有机试剂 - 亚氨、脒
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 中文名称: 1-Boc-3-氰基氮杂环丁烷
• 中文别名: 3-氰吖丁啶；3-氰基氮杂环丁烷-1-甲酸叔丁酯；1-Boc-3-氰吖丁啶；1-BOC-3-氰基吖丁啶；1-叔丁氧羰基-3-氰基氮杂环丁烷；1-叔丁氧羰基-3-腈基氮杂环丁烷
• 英文名称: tert-butyl 3-cyanoazetidine-1-carboxylate
• 英文别名: 1-boc-3-cyanoazetidine
• CAS: 142253-54-1
• 化学式: C₉H₁₄N₂O₂
• mdl: MFCD06796640
• 分子量: 182.222
• InChiKey: WEFREESWPHICPL-UHFFFAOYSA-N

物化性质

• 熔点：
  68-71°C
• 沸点：
  290.2±33.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解，未有已知危险反应。请避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.777
• 拓扑面积：
  53.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xn,Xi
• 安全说明：
  S26,S36/37,S36/37/39,S9
• 危险类别码：
  R20/21/22
• WGK Germany：
  3
• 海关编码：
  2933990090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险品运输编号：
  3439
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  请将贮藏器保持密封状态，并存放在阴凉干燥处。同时，确保工作环境具有良好的通风或排气设施。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Boc-3-cyanoazetidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H319: Causes serious eye irritation
H411: Toxic to aquatic life with long lasting effects
P273: Avoid release to the environment
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Boc-3-cyanoazetidine
CAS number: 142253-54-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H14N2O2
Molecular weight: 182.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途：储存温度为2-8℃

反应信息

• 作为反应物：
  描述：

  1-Boc-3-氰基氮杂环丁烷 在 sodium hydroxide 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 6.25h， 生成 1-(叔丁氧基羰基)-3-甲基氮杂丁烷-3-羧酸
  参考文献：
  名称：

  受保护的 3-卤代氮杂环丁烷的改进的克级合成：氮杂环丁烷-3-羧酸的快速多样化合成

  摘要：

  氮杂环丁烷是在各种天然产物和药物化合物中发现的越来越重要的杂环。受保护的 3-卤代氮杂环丁烷是药物化学中广泛使用的通用构件，已在 1-氮杂双环 [1.1.0] 丁烷的一锅、克级应变释放反应中从市售原料制备。这些中间体随后用于制备一系列高价值的氮杂环丁烷-3-羧酸衍生物，包括首次报道的 1-(叔丁氧基羰基)-3-((三氟甲基)硫代)氮杂环丁烷-3-羧酸的合成。

  DOI：

  10.24820/ark.5550190.p010.549
• 作为产物：
  描述：

  N-Boc-3-羟基氮杂环丁烷 在 三乙胺 作用下， 以 二甲基亚砜 、 乙酸乙酯 为溶剂， 反应 49.0h， 生成 1-Boc-3-氰基氮杂环丁烷
  参考文献：
  名称：

  新型非肽氰胺类化合物，可有效和可逆地抑制人组织蛋白酶K和L。

  摘要：

  鉴定出含有1-氰基吡咯烷基环的化合物是组织蛋白酶K和L的有效抑制剂和可逆抑制剂。原始的铅化合物1抑制组织蛋白酶K和L的IC（50）值分别为0. 37和0.45M。通过取代喹啉部分的化合物1的修饰导致了N-（1-氰基-3-吡咯烷基）苯磺酰胺的合成（2）。发现化合物2是组织蛋白酶K和L的有效抑制剂，组织蛋白酶K的K（i）值为50 nM。用1-氰基氮杂环丁烷取代化合物2的1-氰基吡咯烷使抑制剂的效力提高了10 -折。效力的增加可能是由于该化合物对酶活性位点的硫醇盐的化学反应性增强。当在pH 7的谷胱甘肽存在下进行测定时，证明了这一点。0有利于GSH硫醇盐阴离子的形成。在这些测定条件下，由于在GSH硫醇盐和1-氰基氮杂环丁烷抑制剂之间形成了无活性的复合物，因此1-氰基氮杂环丁烷系列的效能丧失。1-氰基吡咯烷基抑制剂表现出时间依赖性抑制作用，这使我们能够确定与人组织蛋白酶K的缔合和解离速率常数。获得

  DOI：

  10.1021/jm0003440

文献信息

• [EN] DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK<br/>[FR] COMPOSÉS DE DIHYDROPYRROLONAPHTYRIDINONE COMME INHIBITEURS DE JAK
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2010144486A1

  公开（公告）日：2010-12-16

  Disclosed are JAK inhibitors of formula (I) where G1, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. Also disclosed are pharmaceutical compositions, kits and articles of manufacture which contain the compounds, methods and materials for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other diseases, disorders or conditions associated with JAK.

  揭示了式(I)的JAK抑制剂，其中G1、R1、R2、R3、R4、R5、R6和R7在规范中定义。还披露了含有这些化合物的药物组合物、试剂盒和制造物品，制备这些化合物的方法和材料，以及使用这些化合物治疗涉及免疫系统和炎症的疾病、紊乱和症状的方法，包括类风湿关节炎、血液恶性肿瘤、上皮癌（即癌症）和其他与JAK相关的疾病、紊乱或症状。
• [EN] NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES<br/>[FR] NOUVEAUX COMPOSÉS ET COMPOSITIONS PHARMACEUTIQUES ASSOCIÉES POUR LE TRAITEMENT DE MALADIES
  申请人：GALAPAGOS NV

  公开号：WO2020239658A1

  公开（公告）日：2020-12-03

  The present invention discloses compounds according to Formula (I), wherein R1a, R1b, R1c, R2a, W1, W2, X1, X2, X3, Y, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.

  本发明公开了根据式（I）的化合物，其中R1a、R1b、R1c、R2a、W1、W2、X1、X2、X3、Y和Z如本文所定义。本发明涉及化合物、其生产方法、包括其在内的制药组合物，以及使用这些化合物进行预防和/或治疗炎症性疾病、自身炎症性疾病、自身免疫性疾病、增生性疾病、纤维化疾病、移植排斥、涉及软骨周转障碍的疾病、先天软骨畸形、涉及骨周转障碍的疾病、与IL-6过度分泌有关的疾病、与TNFα、干扰素、IL-12和/或IL-23过度分泌有关的疾病、呼吸系统疾病、内分泌和/或代谢性疾病、心血管疾病、皮肤病和/或异常血管生成相关疾病的治疗方法，通过给予本发明的化合物。
• [EN] TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS<br/>[FR] INHIBITEURS TRICYCLIQUES DE GYRASE UTILISABLES COMME AGENTS ANTIBACTÉRIENS
  申请人：TRIUS THERAPEUTICS INC

  公开号：WO2014043272A1

  公开（公告）日：2014-03-20

  Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. In addition, species of tricyclic gyrase inhibitors compounds are also disclosed herein. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

  本文披露了具有化学式I结构的化合物及其药用盐、酯和前药，这些化合物可用作抗菌有效的三环酶抑制剂。此外，本文还披露了三环酶抑制剂化合物的种属。还考虑了相关的药用组合物、用途和制备这些化合物的方法。
• 1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05102877A1

  公开（公告）日：1992-04-07

  1-Azabicyclo[3.2.0]hept-2-ene-2-carboxyic acids having antimicrobial activity have been prepared.

  具有抗微生物活性的1-氮杂二环[3.2.0]庚-2-烯-2-羧酸已制备。
• New thiadiazole derivatives
  申请人：Almirall, S.A.

  公开号：EP2305660A1

  公开（公告）日：2011-04-06

  The present invention relates to thiadiazole derivatives of formula (I), to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent agonists of S1P1 receptors and thus, they are useful in the treatment, prevention or suppression of diseases and disorders known to be susceptible to improvement by sphingosine-1-phosphate receptors agonists (S1P1), such as autoimmune diseases, chronic immune and inflammatory diseases, transplant rejection, malignant neoplastic diseases, angiogenic-related disorders, pain, neurological diseases, viral and infectious diseases.

  本发明涉及式(I)的噻二唑衍生物，它们的制备过程以及包含它们的药物组合物。这些化合物是S1P1受体的强激动剂，因此，它们可用于治疗、预防或抑制那些已知可通过鞘氨醇-1-磷酸受体激动剂（S1P1）改善的疾病和失调，例如自身免疫性疾病、慢性免疫和炎症性疾病、移植排斥反应、恶性肿瘤疾病、与血管生成相关的失调、疼痛、神经系统疾病、病毒和感染性疾病。